Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice

Figure 6

Dapagliflozin treatment limits further progression of existing AAAs. (a) treatment regimens. (b) Mean and SD of aortic diameters at the baseline level (day 0) and 14 days after PPE infusion. (c) Representative abdominal aortic images at the baseline (day 0) and 14 days after PPE infusion. (d) Change in aortic diameter (percent increase over the baseline level) following PPE infusions. Nonparametric Mann–Whitney test, compared with vehicle treatment, (vehicle) or 8 (dapagliflozin at 5 mg/kg). DAPA: dapagliflozin.

(a)

(b)

(c)

(d)